Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Regeneron Pharmaceuticals says the recent decline in its return on invested capital and operating margins does not worry management. The company expects continued revenue growth driven by its biologics Dupixent and Libtayo. It acknowledges market volatility and potential competition from Eylea biosimilars but believes margins will recover over time.
- ▪Regeneron’s ROIC and operating margins have been trending downward, yet the firm’s leadership remains unconcerned.
- ▪Revenue growth is expected to be sustained by the biologic drugs Dupixent and Libtayo.
- ▪The company faces volatility from broader market conditions and possible competition from Eylea biosimilars.
- ▪Management projects that operating margins will improve as the business stabilizes.
Seeking Alpha files mainly under finance. We currently carry 6,316 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925511-regeneron-im-not-concerned-about-the-declining-roic-and-operating-margins"},"author":{"@type":"Person","name":"Robert J.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
